# Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines

> **NCT02568150** · PHASE4 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 45 (actual)

## Conditions studied

- Moderate-severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** Single group, open-label

## Key facts

- **NCT ID:** NCT02568150
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568150, "Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02568150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*